PDS Biotechnology Corp

EU6

Company Profile

  • Business description

    PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.

  • Contact

    303A College Road
    East PrincetonNJ08540
    USA

    T: +1 800 208-3343

    E: [email protected]

    https://www.pdsbiotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    21

Stocks News & Analysis

stocks

OpenAI is going public as the worst value among its peers

Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks

Wide moat healthcare leader remains undervalued

ASX healthcare giant expected to see uptick in demand from emerging markets.
stocks

This US AI winner has been unstoppable. Is it time to sell?

Astonishing results have driven this AI stock into significantly overvalued territory.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,855.9079.60-0.89%
CAC 408,218.2426.05-0.32%
DAX 4024,759.05185.90-0.75%
Dow JONES (US)51,134.69427.24-0.83%
FTSE 10010,368.057.730.07%
HKSE24,961.95291.45-1.15%
NASDAQ26,037.61793.35-2.96%
Nikkei 22566,588.12882.57-1.31%
NZX 50 Index13,161.9760.360.46%
S&P 5007,450.81133.50-1.76%
S&P/ASX 2008,625.1080.00-0.92%
SSE Composite Index4,027.7430.04-0.74%

Market Movers